The Role of Sugammadex in Posotoperative Urinary Retention in Patients Undergoing Pelvic Floor Reconstructive Procedures

Inclusion Criteria: * female patients undergoing a vaginal hysterectomy with the indications of pelvic organ prolapse or abnormal uterine bleeding Exclusion Criteria: * Patients who are already known to have voiding dysfunction * Patients who have a contraindication or intolerance to any of the drugs used in the study * Has a medical condition or surgical procedure that precludes reversal of neuromuscular block at the end of surgery. * Has a neuromuscular disorder(s) that may affect neuromuscular block and/or trial assessments. * Is dialysis-dependent or has severe renal insufficiency, defined as estimated creatinine clearance of \<30 mL/min. * Has or is suspected of having a personal history or family history (parents, grandparents, or siblings) of malignant hyperthermia. * Has or is suspected of having an allergy (e.g., hypersensitivity and/or anaphylactic reaction) to study treatments or its/their excipients, to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used during general anesthesia. * Has received or is planned to receive toremifene within 24 hours before or within 24 hours after study medication administration. * Has any condition that would contraindicate the administration of study medication. * Is pregnant, is attempting to become pregnant, or is lactating. * Is currently participating in or has participated in an interventional clinical trial (including any other current or ongoing trial with a sugammadex treatment arm) with an…